Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Eligibility Criteria

• * Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer.
• * Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) with or without immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage patient before treatment starts, enrollment is allowed from diagnosis up to four weeks after the start of treatment but must be before cycle 2 treatment begins.
• * Patients must be able to comprehend English or Spanish (for survey completion).
• * Patients must be willing to complete surveys online. This can be completed at home, in the clinic or other location.
• * Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment.
• * Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU).
• * Must be receiving treatment at the WF CCC and VCU.
• * Must be diagnosed with non-small cell lung cancer.
• * Must be receiving paclitaxel as part of their chemotherapy in conjunction with ICIs PD-1, PDL1 or CTLA.
• * Must be enrolled before cycle 1 begins
• * Patients with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.).
• * Patients with a history of HIV, hepatitis B or hepatitis C.
• * Patients with active infection who are receiving antibiotic, antifungal or antiviral treatment.